Juno Therapeutics, Inc. (NASDAQ:JUNO) had its price target upped by Raymond James Financial, Inc. from $45.00 to $61.00 in a research note published on Friday. They currently have an outperform rating on the biopharmaceutical company’s stock.

Other research analysts have also issued reports about the stock. Vetr upgraded shares of Juno Therapeutics from a hold rating to a buy rating and set a $28.85 price objective on the stock in a research note on Monday, July 17th. Zacks Investment Research upgraded shares of Juno Therapeutics from a hold rating to a buy rating and set a $32.00 price objective on the stock in a research note on Tuesday, July 11th. BidaskClub lowered shares of Juno Therapeutics from a strong-buy rating to a buy rating in a research note on Tuesday, July 11th. Maxim Group restated a buy rating and set a $56.00 price objective (up from $34.00) on shares of Juno Therapeutics in a research note on Monday, October 9th. Finally, Cowen and Company restated a buy rating and set a $49.00 price objective on shares of Juno Therapeutics in a research note on Friday, October 27th. Three analysts have rated the stock with a sell rating, seven have assigned a hold rating and nine have assigned a buy rating to the stock. Juno Therapeutics currently has a consensus rating of Hold and an average price target of $44.20.

Juno Therapeutics (JUNO) traded up $10.17 during trading on Friday, hitting $58.48. 5,482,719 shares of the stock traded hands, compared to its average volume of 2,320,000. Juno Therapeutics has a one year low of $17.52 and a one year high of $61.59. The company has a current ratio of 4.77, a quick ratio of 5.08 and a debt-to-equity ratio of 0.01.

Juno Therapeutics (NASDAQ:JUNO) last released its quarterly earnings data on Wednesday, November 1st. The biopharmaceutical company reported ($0.73) earnings per share for the quarter, topping the consensus estimate of ($0.80) by $0.07. The company had revenue of $44.80 million for the quarter, compared to analyst estimates of $18.12 million. Juno Therapeutics had a negative net margin of 332.05% and a negative return on equity of 32.54%. Juno Therapeutics’s revenue for the quarter was up 115.4% compared to the same quarter last year. During the same period in the previous year, the business earned ($0.57) EPS. research analysts expect that Juno Therapeutics will post -3.53 EPS for the current fiscal year.

TRADEMARK VIOLATION NOTICE: This news story was reported by Watch List News and is the property of of Watch List News. If you are reading this news story on another publication, it was illegally stolen and republished in violation of United States & international copyright & trademark law. The correct version of this news story can be viewed at https://www.watchlistnews.com/juno-therapeutics-inc-juno-given-new-61-00-price-target-at-raymond-james-financial-inc/1678635.html.

In other Juno Therapeutics news, EVP Robert Azelby sold 6,666 shares of the business’s stock in a transaction dated Thursday, November 2nd. The shares were sold at an average price of $54.95, for a total value of $366,296.70. Following the completion of the sale, the executive vice president now owns 79,998 shares of the company’s stock, valued at approximately $4,395,890.10. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, General Counsel Bernard J. Cassidy sold 28,000 shares of the business’s stock in a transaction dated Thursday, September 14th. The shares were sold at an average price of $44.92, for a total transaction of $1,257,760.00. Following the completion of the sale, the general counsel now directly owns 55,970 shares of the company’s stock, valued at approximately $2,514,172.40. The disclosure for this sale can be found here. Insiders sold a total of 91,670 shares of company stock valued at $3,917,857 in the last three months. Insiders own 15.26% of the company’s stock.

A number of hedge funds and other institutional investors have recently bought and sold shares of JUNO. UBS Asset Management Americas Inc. boosted its holdings in Juno Therapeutics by 76.4% in the 1st quarter. UBS Asset Management Americas Inc. now owns 29,900 shares of the biopharmaceutical company’s stock valued at $663,000 after purchasing an additional 12,947 shares during the period. Parametric Portfolio Associates LLC boosted its holdings in Juno Therapeutics by 88.6% in the 1st quarter. Parametric Portfolio Associates LLC now owns 39,826 shares of the biopharmaceutical company’s stock valued at $884,000 after purchasing an additional 18,713 shares during the period. JPMorgan Chase & Co. boosted its holdings in Juno Therapeutics by 2,185.8% in the 1st quarter. JPMorgan Chase & Co. now owns 62,746 shares of the biopharmaceutical company’s stock valued at $1,393,000 after purchasing an additional 60,001 shares during the period. Teachers Advisors LLC boosted its holdings in Juno Therapeutics by 5.8% in the 1st quarter. Teachers Advisors LLC now owns 64,365 shares of the biopharmaceutical company’s stock valued at $1,428,000 after purchasing an additional 3,531 shares during the period. Finally, Legal & General Group Plc boosted its holdings in Juno Therapeutics by 220.6% in the 1st quarter. Legal & General Group Plc now owns 25,858 shares of the biopharmaceutical company’s stock valued at $574,000 after purchasing an additional 17,792 shares during the period. 67.18% of the stock is owned by hedge funds and other institutional investors.

Juno Therapeutics Company Profile

Juno Therapeutics, Inc (Juno) is a biopharmaceutical company, which is focused on developing cellular immunotherapies for the treatment of cancer. The Company is developing cell-based cancer immunotherapies based on its chimeric antigen receptor (CAR) and T cell receptor (TCR) technologies to genetically engineer T cells to recognize and kill cancer cells.

Analyst Recommendations for Juno Therapeutics (NASDAQ:JUNO)

Receive News & Ratings for Juno Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Juno Therapeutics Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.